Cargando…

Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States

BACKGROUND: As real-world data resources expand and improve, there will increasingly be opportunities to study the effectiveness of interventions. There is a need to ensure that study designs explore potential sources of bias and either acknowledge or mitigate them, in order to improve the accuracy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hess, Lisa M, Grabner, Michael, Wang, Liya, Liepa, Astra M, Li, Xiaohong Ivy, Cui, Zhanglin Lin, Bowman, Lee, Schelman, William R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205419/ https://www.ncbi.nlm.nih.gov/pubmed/32431558 http://dx.doi.org/10.2147/POR.S241427

Ejemplares similares

The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer
por: Hess, Lisa M., et al.
Publicado: (2020)

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019)

Data Integration to Improve Real-world Health Outcomes Research for Non–Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration
por: Grabner, Michael, et al.
Publicado: (2021)

Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States
por: Mehta, Rutika, et al.
Publicado: (2023)

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea
por: Carter, Gebra Cuyun, et al.
Publicado: (2017)

Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data
por: Hess, Lisa M., et al.
Publicado: (2015)

Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database
por: Karve, Sudeep, et al.
Publicado: (2015)

Early Weight Loss as a Prognostic Factor in Patients with Advanced Gastric Cancer: Analyses from REGARD, RAINBOW, and RAINFALL Phase III Studies
por: Mansoor, Wasat, et al.
Publicado: (2021)

Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer
por: Smyth, Emily Nash, et al.
Publicado: (2016)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016)

ASO Author Reflections: Real-World Conclusions on Locoregionally Recurrent Colon Cancer
por: Swartjes, Hidde, et al.
Publicado: (2022)

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain
por: Poveda, José Luis, et al.
Publicado: (2023)

Collaborative Automation Reliably Remediating Erroneous Conclusion Threats (CARRECT)
por: Lansey, Jonathan C., et al.
Publicado: (2013)

Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines
por: Durães, Fernando, et al.
Publicado: (2019)

Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
por: Nix, Nancy M., et al.
Publicado: (2019)

Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States
por: Pizzicato, Lia N, et al.
Publicado: (2023)

Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease
por: Di Luca, Daniel Garbin, et al.
Publicado: (2022)

Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan
por: Maeda, Hideki, et al.
Publicado: (2022)

USING REAL-WORLD EVIDENCE TO SUPPORT THE FDA REGULATORY APPROVAL: METHODOLOGICAL CONSIDERATIONS
por: Lu, Kevin, et al.
Publicado: (2022)

Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
por: Mody, Reema, et al.
Publicado: (2019)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data
por: Clouth, Johannes, et al.
Publicado: (2018)

Conclusion
por: CERN. Geneva
Publicado: (2018)

Conclusion
Publicado: (1983)

Conclusion
Publicado: (1996)

Conclusion
Publicado: (2001)

Conclusion
por: Cortes-Funes, H
Publicado: (2003)

Conclusions
por: Rubbia, Carlo
Publicado: (1994)

Conclusions
por: Montanet, Lucien
Publicado: (1973)

Conclusions
por: Rosner, J L
Publicado: (1973)

Conclusion
por: Moscicki, Jakub
Publicado: (2021)

Conclusions
por: Hitzemann, Robert, et al.
Publicado: (2008)

Conclusion
por: Dieye, Adama
Publicado: (2020)

Conclusion
por: Clark, Anthony E.
Publicado: (2020)

Conclusions
por: Buckledee, Steve
Publicado: (2020)

Conclusion
por: Drew, Joseph
Publicado: (2020)

Conclusion
por: Fong, Simon James, et al.
Publicado: (2020)

Conclusion
por: McFee, R.B.
Publicado: (2020)

Conclusion
por: McFee, Robin B.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nf77mqgvqftfqntvma16442n9b